Figure 4.
Survival curves of NPM1-mutated AML (de novo vs therapy-related) belonging to the ELN favorable risk (NPM1 mutated, FLT3-ITD low or negative, nonadverse karyotype).

Survival curves of NPM1-mutated AML (de novo vs therapy-related) belonging to the ELN favorable risk (NPM1 mutated, FLT3-ITD low or negative, nonadverse karyotype).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal